STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07743138
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • ACC
  • Evaluate
  • Ivonescimab
  • PPGL
  • Phase II
  • Unresectable Pheochromocytoma
  • Unresectable/Metastatic Adrenocortical Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ACC or PPGL.

Key Dates

First listed
Aug 3, 2026
Start date
Feb 7, 2027
Status verified
Jul 2026
Primary completion
May 1, 2028
Completion
May 1, 2030

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1
    Treatment with Ivonescimab (IV) Q3W For ACC
  • Experimental: Cohort 2
    Treatment with Ivonescimab (IV) Q3W For PPGL Suspended: No

Primary Outcome Measure

Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Matthew Campbell, MD
[email protected]
713-563-3877
Matthew Campbell, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies